Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Oklahoma Medical Research Foundation has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, indicating separate examination paths within the same technology area.
MOSELEY II, NELSON B is the busiest examiner, with 1 pending matter. Counsel should track the two records independently while maintaining consistent explanations of shared biotechnology concepts where the disclosures support them.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 1 | 67.9% | +41.7% |
| COUNTS, GARY W | 1 | 58.9% | +29.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016384 | METHOD FOR DETERMINING WHETHER A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENT IS UNDERGOING A PRE-FLARE EVENT | COUNTS, GARY W | 5d |
| 18411242 | COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS USING A CD14 INHIBITOR | MOSELEY II, NELSON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016384 | METHOD FOR DETERMINING WHETHER A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENT IS UNDERGOING A PRE-FLARE EVENT | COUNTS, GARY W | 5d |
| 18411242 | COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS USING A CD14 INHIBITOR | MOSELEY II, NELSON B | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18411242 | COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS USING A CD14 INHIBITOR | MOSELEY II, NELSON B | 1642 | §103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18016384 | METHOD FOR DETERMINING WHETHER A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENT IS UNDERGOING A PRE-FLARE EVENT | COUNTS, GARY W | 1678 | §101§103 | Final Rejection | 5d | Pending | Jan 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOklahoma Medical Research Foundation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Nelson B Moseley II has the most, with 1 of Oklahoma Medical Research Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
